SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Every figure this model derived for SUPN, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 1,124,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 548,167,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 723,496,000 AssetsCurrent 2026-06-30
current liabilities 347,378,000 LiabilitiesCurrent 2026-06-30
equity 1,031,226,000 StockholdersEquity 2026-06-30
interest expense 0 InterestExpenseDebt 2025-12-31
ocf 19,911,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 830,438,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 34,596,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up SUPN on one particular measure came for.

RatioValue
cash operating margin0.7
current ratio2.08
current ratio reported2.08
deferred revenue growth118.97
dilution pct0.88
fcf margin2.26
growth cv1.18
operating margin-15.71
owner earnings margin-1.9
revenue growth24.85
revenue growth per share23.76
roic-21.34
rule of 409.14
sbc pct revenue4.17

What to be careful about

What this model itself distrusts about SUPN's figures. Written by the derivation as it ran, not added afterwards.